KCTBASE

Clinical Implications of VEGF, TGF-β1, and IL-1β in Patients with Advanced Non-small Cell Lung Cancer

Cancer Research and Treatment 2013년 45권 4호 p.325 ~ p.333

김지원(Kim Ji-Won) - Seoul National University College of Medicine Department of Internal Medicine
고영일(Koh Young-Il) - Seoul National University College of Medicine Department of Internal Medicine
김동완(Kim Dong-Wan) - Seoul National University College of Medicine Department of Internal Medicine
안용운(Ahn Yong-Oon) - Seoul National University College of Medicine Department of Internal Medicine
김태민(Kim Tae-MIn) - Seoul National University College of Medicine Department of Internal Medicine
한세원(Han Sae-Won) - Seoul National University College of Medicine Department of Internal Medicine
오도연(Oh Do-Youn) - Seoul National University College of Medicine Department of Internal Medicine
이세훈(Lee Se-Hoon) - Seoul National University College of Medicine Department of Internal Medicine
임석아(Im Seock-Ah) - Seoul National University College of Medicine Department of Internal Medicine
김태유(Kim Tae-You) - Seoul National University College of Medicine Department of Internal Medicine
허대석(Heo Dae-Seog) - Seoul National University College of Medicine Department of Internal Medicine
방영주(Bang Yung-Jue) - Seoul National University College of Medicine Department of Internal Medicine

Abstract

Purpose: Vascular endothelial growth factor (VEGF)-A, VEGF165b, interleukin (IL)-1β, and transforming growth factor (TGF)-β1 are known to influence tumor angiogenesis. Clinical implications of these cytokines need to be elucidated.

Materials and Methods: Using clinical data and baseline serum samples of 140 consecutive patients with advanced non-small cell lung cancer who received platinum-based combination chemotherapy, we investigated the association among serum cytokine levels, treatment outcomes, as well as leukocyte and platelet counts.

Results: The median age of patients was 64 years (range, 26 to 86 years). The male to female ratio was 104:36. High TGF-β1 and IL-1β levels were associated with shorter progression-free survival, and high VEGF-A and IL-1β levels were associated with shorter overall survival in the univariate analysis. VEGF165b was not related to the treatment outcomes. Leukocytosis and thrombocytosis were associated with shorter overall survival. The multivariate analysis demonstrated that VEGF-A, IL-1β, and leukocytosis were significant prognostic factors (p=0.0497, p=0.047, and p<0.001, respectively). Leukocytosis was not associated with recent pneumonia (p=0.937) and correlated with VEGF-A (p<0.001) and TGF-β1 (p=0.020) levels.

Conclusion: Serum VEGF-A, TGF-1β, and IL-1β levels, in addition to leukocyte and platelet counts, are shown to be associated with clinical outcomes. Leukocyte and platelet counts are correlated with serum VEGF-A and TGF-β1 levels.

키워드

Vascular endothelial growth factor, Interleukin-1beta, Transforming growth factor beta1, Leukocytes, Blood platelets, Non-small cell lung carcinoma

KMID : 0939920130450040325

원문 및 링크아웃 정보

학회

등재저널 정보

주제코드

주제명(Target field)

연구대상(Population)

연구참여(Sample size)

대상성별(Gender)

질병특성(Condition Category)

연구환경(Setting)

연구설계(Study Design)

연구기간(Period)

중재방법(Intervention Type)

중재명칭(Intervention Name)

키워드(Keyword)

유효성결과(Recomendation)

Leukocytosis and thrombocytosis were associated with shorter overall survival. VEGF-A, IL-1β, and leukocytosis were significant prognostic factors.

연구비지원(Fund Source)

근거수준평가(Evidence Hierarchy)

출판년도(Year)

참여저자수(Authors)

대표저자

DOI

KCD코드

ICD 03

건강보험코드